New hope for bladder cancer patients: immunotherapy may help avoid bladder removal

NCT ID NCT03697850

Ongoing Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to see how long they remain cancer-free, with a focus on preserving the bladder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to: If successful, this could offer a way to control bladder cancer without removing the bladder, potentially preserving quality of life for patients who are not candidates for surgery.
What could go wrong: This is an early-phase, single-arm study with only 79 participants, so results may not apply to all patients. Immunotherapy can cause side effects like inflammation in healthy organs, and the cancer may still return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, France
Centre Azureen de Cancerologie

Mougins, 06250, France
Centre Georges Francois Leclerc

Dijon, France
Centre Jean Perrin

Clermont-Ferrand, France
Centre Oscar Lambret

Lille, France
Chu Lyon Sud

Pierre-Bénite, France
Gustave Roussy

Villejuif, 94800, France
Hopital Saint Louis

Paris, France
Hôpital Pitie Salpetriere

Paris, France
INSTITUT de CANCEROLOGIE DE L'OUEST - site René Gauducheau

Saint-Herblain, France
Icm Val D'Aurelle

Montpellier, France
Institut Bergonie

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.